Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome
In this study, we carried out the clinical and laboratory research of severe PMS (premenstrual syndrome) treatment in premenopausal age women. Herein, 37 women were examined and observed before the beginning of treatment and three months after it. Medication containing micronized progesterone was us...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2017-09-01
|
| Series: | Current Issues in Pharmacy and Medical Sciences |
| Subjects: | |
| Online Access: | http://www.degruyter.com/view/j/cipms.2017.30.issue-3/cipms-2017-0025/cipms-2017-0025.xml?format=INT |
| _version_ | 1818694191881912320 |
|---|---|
| author | Horbatiuk Olha Binkovska Alla Herych Olena Ropotan Andriy Zhylko Natalia Mandziy Iryna Buleza Iryna |
| author_facet | Horbatiuk Olha Binkovska Alla Herych Olena Ropotan Andriy Zhylko Natalia Mandziy Iryna Buleza Iryna |
| author_sort | Horbatiuk Olha |
| collection | DOAJ |
| description | In this study, we carried out the clinical and laboratory research of severe PMS (premenstrual syndrome) treatment in premenopausal age women. Herein, 37 women were examined and observed before the beginning of treatment and three months after it. Medication containing micronized progesterone was used for treatment (sublingually, 100 mg from 11 to 25 days of menstrual cycle). After three months of micronized progesterone treatment, 86.5% of all women-participants of the study were observed to have full regression of clinical symptoms, while 13.5% of all patients were observed to have decrease in clinical symptoms of severe PMS. Moreover, hormonal research results revealed significant (1.3 times) decrease in LH (Luteinizing hormone) level and (1.3 times) increase in progesterone level after three months of treatment (р<0.05). The high bio-accessibility of the medication and its natural structure made it possible to decrease the dose and avoid risks of hepatotoxicity. |
| first_indexed | 2024-12-17T13:25:40Z |
| format | Article |
| id | doaj.art-5bf8c91308304d548f45642b63908106 |
| institution | Directory Open Access Journal |
| issn | 2300-6676 |
| language | English |
| last_indexed | 2024-12-17T13:25:40Z |
| publishDate | 2017-09-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Current Issues in Pharmacy and Medical Sciences |
| spelling | doaj.art-5bf8c91308304d548f45642b639081062022-12-21T21:46:45ZengSciendoCurrent Issues in Pharmacy and Medical Sciences2300-66762017-09-0130313814110.1515/cipms-2017-0025cipms-2017-0025Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndromeHorbatiuk Olha0Binkovska Alla1Herych Olena2Ropotan Andriy3Zhylko Natalia4Mandziy Iryna5Buleza Iryna6Department of Obstetrics and Gynecology, Faculty of Postgraduate Education, National Pirogov Memorial Medical University, 29000 Vodoprovidna 8/1, Khmelnytsky, UkraineDepartment of Obstetrics and Gynecology, Faculty of Postgraduate Education, National Pirogov Memorial Medical University, 29000 Vodoprovidna 8/1, Khmelnytsky, UkraineDepartment of Obstetrics and Gynecology, Faculty of Postgraduate Education, National Pirogov Memorial Medical University, 29000 Vodoprovidna 8/1, Khmelnytsky, UkraineCity Prenatal Center, Khmelnytsky, UkraineCity Prenatal Center, Khmelnytsky, UkraineCity Prenatal Center, Khmelnytsky, UkraineCity Prenatal Center, Khmelnytsky, UkraineIn this study, we carried out the clinical and laboratory research of severe PMS (premenstrual syndrome) treatment in premenopausal age women. Herein, 37 women were examined and observed before the beginning of treatment and three months after it. Medication containing micronized progesterone was used for treatment (sublingually, 100 mg from 11 to 25 days of menstrual cycle). After three months of micronized progesterone treatment, 86.5% of all women-participants of the study were observed to have full regression of clinical symptoms, while 13.5% of all patients were observed to have decrease in clinical symptoms of severe PMS. Moreover, hormonal research results revealed significant (1.3 times) decrease in LH (Luteinizing hormone) level and (1.3 times) increase in progesterone level after three months of treatment (р<0.05). The high bio-accessibility of the medication and its natural structure made it possible to decrease the dose and avoid risks of hepatotoxicity.http://www.degruyter.com/view/j/cipms.2017.30.issue-3/cipms-2017-0025/cipms-2017-0025.xml?format=INTPMStreatmentper menopausemicronized progesterone |
| spellingShingle | Horbatiuk Olha Binkovska Alla Herych Olena Ropotan Andriy Zhylko Natalia Mandziy Iryna Buleza Iryna Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome Current Issues in Pharmacy and Medical Sciences PMS treatment per menopause micronized progesterone |
| title | Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome |
| title_full | Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome |
| title_fullStr | Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome |
| title_full_unstemmed | Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome |
| title_short | Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome |
| title_sort | using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome |
| topic | PMS treatment per menopause micronized progesterone |
| url | http://www.degruyter.com/view/j/cipms.2017.30.issue-3/cipms-2017-0025/cipms-2017-0025.xml?format=INT |
| work_keys_str_mv | AT horbatiukolha usingmicronizedprogesteronefortreatmentofpremenopausalagewomensufferingfromseverepremenstrualsyndrome AT binkovskaalla usingmicronizedprogesteronefortreatmentofpremenopausalagewomensufferingfromseverepremenstrualsyndrome AT herycholena usingmicronizedprogesteronefortreatmentofpremenopausalagewomensufferingfromseverepremenstrualsyndrome AT ropotanandriy usingmicronizedprogesteronefortreatmentofpremenopausalagewomensufferingfromseverepremenstrualsyndrome AT zhylkonatalia usingmicronizedprogesteronefortreatmentofpremenopausalagewomensufferingfromseverepremenstrualsyndrome AT mandziyiryna usingmicronizedprogesteronefortreatmentofpremenopausalagewomensufferingfromseverepremenstrualsyndrome AT bulezairyna usingmicronizedprogesteronefortreatmentofpremenopausalagewomensufferingfromseverepremenstrualsyndrome |